Template:Microscopic evaluation of neoadjuvant invasive cancer
Jump to navigation
Jump to search
Author:
Mikael Häggström [note 1]
If not already stated, look for clues that neoadjuvant treatment has been given, that is, when the patient has received chemotherapy, endocrine therapy and/or radiotherapy before the excision. Look more thoroughly for it if the duration between a previous biopsy and subsequent excision is longer than usual. It's usually about a month.[1]
In neoadjuvant cases , perform:
- Measurement of the tumor bed which generally manifests as a fibroelastic area.
- Classification of residual cancer, for which there are multiple systems, mainly Residual Cancer Burden (RCB)[note 2] and the American Joint Committee on Cancer post-neoadjuvant therapy staging system (yAJCC).[2]
Contents
Notes
- ↑ For a full list of contributors, see article history. Creators of images are attributed at the image description pages, seen by clicking on the images. See Patholines:Authorship for details.
- ↑ A calculator and explanations for calculating RCB is found at: http://www3.mdanderson.org/app/medcalc/index.cfm?pagename=jsconvert3
Main page
References
- ↑ van Esser S, Peters NH, van den Bosch MA, Mali WP, Peeters PH, Borel Rinkes IH (2009). "Surgical outcome of patients with core-biopsy-proven nonpalpable breast carcinoma: a large cohort follow-up study. ". Ann Surg Oncol 16 (8): 2252-8. doi:. PMID 19437077. PMC: 2711911. Archived from the original. .
- ↑ Campbell JI, Yau C, Krass P, Moore D, Carey LA, Au A (2017). "Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). ". Breast Cancer Res Treat 165 (1): 181-191. doi:. PMID 28577078. PMC: 5653207. Archived from the original. .
Image sources
